天坛生物(600161) - 2017 Q1 - 季度业绩预告(更正)

Financial Performance - The company expects to achieve a net profit of approximately 99.58 million yuan for Q1 2017, a turnaround from a loss of 0.676 million yuan in the same period last year [2]. - Blood products revenue reached 351.42 million yuan, representing a year-on-year growth of 25.82%, with a net profit of 126.48 million yuan, up 56.29% compared to the previous year [2]. - Preventive products revenue increased to 172.84 million yuan, showing a significant year-on-year growth of 104.01%, although the net profit was a loss of 27.72 million yuan, which is a reduction in loss by 64.48% [3].